Results 81 to 90 of about 15,823 (164)

Tumor‐Responsive PLGA‐SS‐HA Nanoparticles for Zinc Complex Delivery Suppress Prostate Cancer via TR3/FTH1 Pathway

Macromolecular Materials and Engineering, Volume 311, Issue 8, August 2026.
A tumor‐responsive PLGA‐SS‐HA nanoplatform enables glutathione‐triggered delivery of zinc complexes to prostate cancer cells. Enhanced intracellular zinc accumulation induces oxidative stress, mitochondrial dysfunction, and apoptosis through activation of the TR3/FTH1 signaling pathway.
Ding Ma, Sheng Ge, Ruimin Ren, Yongqiang Fu   +3 more
wiley   +1 more source

Early‐Onset Prostate Cancer: Epidemiology, Risk Factors, Biology, Clinical Features, Management, and Early Detection

MedComm, Volume 7, Issue 8, August 2026.
EOPC is a distinct clinicopathological entity separable from SOPC, differing fundamentally in genetic susceptibility, TMPRSS2:ERG fusion frequency, and survival outcomes. Although research remains nascent, this review provides the first comprehensive synthesis of current evidence, offering a critical foundation to guide future investigations into this ...
Xingyu Xiong, Weizhen Zhu, Weichao Huang, Shiyu Zhang, Qi Deng, Jie Yang, Hang Xu, Qiang Wei, Lu Yang   +8 more
wiley   +1 more source

Cardiovascular Diseases and Cancer: Convergent Proteostasis Networks at the Crossroads of Mechanisms and Therapeutic Opportunities

MedComm, Volume 7, Issue 8, August 2026.
The disruption of proteostasis, encompassing the ubiquitin–proteasome system, autophagy, UPR/ER stress, and chaperone function, represents a fundamental mechanism shared by both cancer and cardiovascular diseases. While these pathways frequently facilitate tumor progression, they are crucial for maintaining proteostasis in cardiac tissue. Consequently,
Jacob Eli García Torres, Norbert Frey, Ashraf Yusuf Rangrez   +2 more
wiley   +1 more source

Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 8, August 2026.
The graphic summarizes the design principles, intracellular trafficking, clinical progress, challenges, and future directions of antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs). ADCs consist of a tumor‐targeting antibody, a chemical linker, and a potent payload, whereas PDCs use peptide ligands to deliver cytotoxic, radionuclide, or ...
Ruxi Zheng, Shuiquan Li, Zhigang Zhang, Mengke Niu, Jing Fei, Jiaojiao Zhang, Jianwei Zhou, Kongming Wu, Ming Yi, Tianye Li   +9 more
wiley   +1 more source

Nucleotide Metabolism in Health and Disease

MedComm, Volume 7, Issue 8, August 2026.
Nucleotide metabolism, including de novo synthesis, salvage pathways, and catabolism, when dysregulated contributes to cancer, immune disorders, metabolic and urological diseases, and radiation injury. Metabolites such as adenosine, cGAMP, NAD, and cAMP and enzymes like RNR are promising therapeutic targets and biomarkers.
Xiaoying Zhao, Yiyu Zeng, Yike Xu, Shu Rao, Mouna Khouchani, Hassna Soummane, Jingyi Li, Rui Liu   +7 more
wiley   +1 more source

Prognostic Role of Serum Neuron‐Specific Enolase at Baseline and its Early Dynamics in Metastatic Castration‐Resistant Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors

The Prostate, Volume 86, Issue 11, Page 1187-1194, August 2026.
ABSTRACT Background Outcomes of metastatic castration‐resistant prostate cancer (mCRPC) treated with androgen receptor signaling inhibitors (ARSIs) vary widely and may not be fully reflected by PSA and standard clinicopathologic factors. We evaluated the prognostic value of serum neuron‐specific enolase (NSE) at baseline and early on‐treatment dynamics.
Ondřej Fiala, Michaela Tkadlecová, Zuzana Váchalová, Milan Hora, Jan Králíček, Petr Stránský Jr., Václav Liška, Matteo Santoni, Giuseppe Luigi Banna, Kristýna Pivovarčíková, Ondřej Topolčan, Jindřich Fínek   +11 more
wiley   +1 more source

Efficacy, Safety, and Cost‐Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non‐Metastatic Castration‐Resistant Prostate Cancer: A Multicenter Retrospective Study

The Prostate, Volume 86, Issue 11, Page 1233-1240, August 2026.
ABSTRACT Background The introduction of novel androgen receptor signaling inhibitors (ARSIs) has substantially transformed the systemic treatment landscape for non‐metastatic castration‐resistant prostate cancer (nmCRPC). Unfortunately, ARSI therapy is associated with considerable adverse events (AEs) and high medical costs.
Himawari Asanuma, Naoki Fujita, Shumon Kato, Yohei Kawashima, Masanao Shinohara, Ryuji Tabata, Fumiya Yoneyama, Ryuma Tanaka, Takuya Oishi, Hikari Miura, Kyo Togashi, Kazutaka Okita, Hirotaka Horiguchi, Toshikazu Tanaka, Daisuke Noro, Yuichiro Suzuki, Satoshi Sato, Chikara Ohyama, Shingo Hatakeyama   +18 more
wiley   +1 more source

Deciphering the Functional Mechanisms of eIF3f in Tumors and Exploring Targeted Therapies

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Eukaryotic translation initiation factor 3 subunit F (eIF3f) is a critical component of the eIF3 complex and plays a pivotal role in diverse biological processes, including cell proliferation, apoptosis, adhesion, and transcriptional regulation.
Yujinpeng Hao, Jun Shao, Naqi Lian, Mianli Bian   +3 more
wiley   +1 more source

Immune-inflammation index as prognostic markers in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. [PDF]

Front Oncol
Qin Z, Liu R, Jing S, Guo C, Li W.
europepmc   +1 more source

Isothiocyanates as Ferroptosis Inducers to Promote Cancer Cell Death

Phytotherapy Research, Volume 40, Issue 8, Page 5119-5131, August 2026.
ABSTRACT Cancer remains a leading cause of global mortality, with the therapeutic efficacy of anticancer drugs often hampered by late diagnosis and the development of chemotherapy resistance. Ferroptosis is an iron‐dependent form of regulated non‐apoptotic cell death driven by lipid peroxidation.
Valentina Citi, Renda Chahna, Francesca Maffei, Alma Martelli, Vincenzo Calderone, Carmela Fimognari, Eleonora Turrini   +6 more
wiley   +1 more source